7-day point-prevalence smoking abstinence

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49